全球 Bardet-Biedl 综合征市场 – 行业趋势和 2030 年预测

Biedl-Bardet 综合征市场分析和规模

Biedl-Bardet 综合征 (BBS) 是一种影响多个身体系统的遗传性疾病。传统上，该病有六个特征。肥胖可能是 BBS 患者的一个问题，尤其是腹部周围的脂肪沉积。他们通常还患有智力障碍。肾脏、眼睛和阴道功能经常受到影响。BBS 患者的手上也可能有多余的手指。即使是同一个家庭的成员，BBS 的程度也有很大差异。 

Data Bridge Market Research 分析，全球 Bardet-Biedl 综合征 市场规模在 2022 年为 3.4922 亿美元，到 2030 年可能达到 5.2829 亿美元，预计在 2023 年至 2030 年的预测期内复合年增长率为 5.9%。由于慢性病患病率不断上升，“基因检测”细分市场占据了市场主导地位。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

Biedl-Bardet 综合征市场范围和细分

Market Definition

Bardet-Biedl syndrome (BBS) is a rare hereditary multisystem condition characterized by a wide range of mild manifestations, including obesity, genitourinary, retinal dystrophy, polydactyly, and renal defects, learning difficulty, and hypogonadism. Treatment and multidisciplinary management are required. There is no targeted treatment available. The majority of manifestations are treated in the same way that the general public is (obesity, learning disability, kidney anomalies). Surgery is also recommended for the correction of genital anomalies and polydactyly.

Biedl-Bardet Syndrome Market Dynamics

Drivers

• Rising incidences of obesity

The surging incidences of obesity are a major factor driving the market's growth rate. Obesity is a prevalent component of Bardet-Biedl syndrome (BBS), thus it's especially crucial to address it. Only a few people with Bardet-Biedl syndrome (BBS) have undergone bariatric surgery with gastric banding or sleeve surgery. In those patients, surgery was linked to a 25 percent weight decrease that was maintained 12 months later. Long-term follow-up of these individuals is being done to investigate if bariatric surgery has a function in patients with Bardet-Biedl syndrome (BBS).

• Rising healthcare infrastructure

Enhanced healthcare infrastructure, including advanced medical equipment and facilities, can lead to improved diagnostic capabilities. This is crucial for rare diseases like Bardet-Biedl syndrome, which may require specialized testing and expertise for accurate diagnosis.

Opportunities

• Increasing number of research and development activities

Increasing research activities can lead to the discovery of new genetic markers and diagnostic tools for Bardet-Biedl syndrome. This can enhance the accuracy and efficiency of diagnosis. Enhanced research can facilitate the initiation of clinical trials for potential treatments or interventions. This provides patients with the opportunity to participate in experimental therapies.

• Increasing technological advancements

Technological advancements in genetic testing and sequencing have the potential to make the diagnosis of BBS faster, more accurate, and more accessible. Next-generation sequencing technologies can identify the specific genetic mutations associated with BBS. Advanced data analysis and bioinformatics tools can assist researchers and clinicians in identifying genetic variations and understanding the complex genetic underpinnings of BBS.

Restrains

• Strict regulations and guidelines

Regulations govern the conduct of clinical trials, including those related to rare diseases. Researchers and pharmaceutical companies conducting clinical trials for potential BBS treatments must adhere to ethical and safety standards set by regulatory agencies.

• High cost of treatment

Managing the complex medical needs associated with BBS can be costly, and the financial burden on patients and their families can be significant. Coping with the financial burden of high treatment costs, especially when combined with the emotional and psychological impact of living with a rare disease, can place additional stress on individuals and their families.

Challenges

• Diagnostic challenges

The diagnosis of BBS can be challenging due to its genetic complexity. Identifying the specific genetic mutations responsible for the condition may require specialized testing, and not all healthcare providers are familiar with the syndrome.

This Bardet-Biedl syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Bardet-Biedl syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In February 2022, Rhythm Pharmaceuticals had announced the United States Food and Drug Administration (FDA) extension of review period for IMCIVREE (setmelanotide) for patients suffering from Bardet-Biedl syndrome and Alström syndrome. In the United States, IMCIVREE is approved for the treatment of obesity in adults and children aged 6 and up who have a deficiency in proprotein convertase subtilisin/kexin type 1 (PCSK1), proopiomelanocortin (POMC), or leptin receptor (LEPR), as determined by genetic testing revealing pathogenic, likely pathogenic, or unknown significance variants in the PCSK1, POMC or LEPR genes 

Global Bardet-Biedl Syndrome Market Scope

Bardet-Biedl 综合征市场根据遗传、诊断、治疗、发病年龄、最终用户和分销渠道进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

遗产

• 寡基因
• 常染色体隐性

诊断

• 视网膜电图 (ERG)
• 基因检测
• 其他的

治疗

• 外科手术
• 肾移植
• 药物
• 治疗
• 抑制疗法
• 基因治疗
• 干细胞治疗
• 其他的

发病年龄

• 童年
• 新生儿
• 婴儿期
• 青少年

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

Bardet-Biedl 综合征市场区域分析/见解

对 Bardet-Biedl 综合征市场进行了分析，并按国家、遗传、诊断、治疗、发病年龄、最终用户和分销渠道提供了市场规模洞察和趋势。

市场报告涉及的国家包括美国、加拿大、墨西哥、德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲其他地区、巴西、阿根廷和南美洲其他地区。

由于 Bardet-Biedl 综合征的患病率不断上升，北美预计将占据市场主导地位并继续保持最高的增长率，而医疗支出的增加将进一步推动该地区市场的增长率。此外，主要关键参与者的不断增加将进一步推动该地区市场的增长率。由于该地区医疗基础设施的发展，预计亚太地区将在 2023-2030 年预测期内实现增长。此外，政府举措的不断增加也将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。       

医疗保健基础设施增长安装基础和新技术渗透

Bardet-Biedl 综合征市场还为您提供每个国家/地区资本设备医疗支出增长、Bardet-Biedl 综合征市场不同类型产品的安装基数、使用生命线曲线的技术影响以及医疗监管情景的变化及其对 Bardet-Biedl 综合征市场的影响的详细市场分析。数据涵盖 2010-2020 年的历史时期。

竞争格局和 Bardet-Biedl 综合征市场份额分析

Bardet-Biedl 综合征市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对 Bardet-Biedl 综合征市场的关注有关。

Bardet-Biedl 综合征市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（爱尔兰）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• 默克公司（美国）
• 艾尔建（爱尔兰）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• Hikma Pharmaceuticals PLC（英国）
• 百时美施贵宝公司 (美国)
• 拜耳公司（德国）
• 勃林格殷格翰国际有限公司（德国）
• Dr. Reddy's Laboratories Ltd.（印度）
• 吉利德科学公司（美国）
• 安进公司 (美国)
• 礼来公司 (美国)
• AbbVie Inc.（美国）
• 鲁冰花（印度）
• 艾尔建（爱尔兰）

SKU-68498